A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma

Brief description of study

The purpose of this study is to see if there is any effect on your cancer after being treated with antibiotics (a drug used to kill bacteria) and pembrolizumab. Ciprofloxacin and Metronidazole are the antibiotics being used in this trial. They work by decreasing and/or eliminating bacteria in the body, thereby altering your microbiome (the organisms in your body). Pembrolizumab is an anti-cancer drug currently used to treat patients with melanoma (skin cancer) and non-small cell lung cancer that has spread to other organs. It works by reinvigorating the patient’s own immune system, allowing it to target and destroy cancer cells. Pembrolizumab is marketed by the pharmaceutical company Merck & Co., which will be providing pembrolizumab free of charge to patients participating in this study. Pembrolizumab is not currently approved by the US Food and Drug Administration (FDA). You have been asked to participate in this study because you have resectable (able to be surgically removed) Pancreatic Adenocarcinoma (Cancer).


Clinical Study Identifier: s18-00137
ClinicalTrials.gov Identifier: NCT03891979
Principal Investigator: Deirdre J Cohen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.